Goodsurance

Drug prices & Part D

Medicare's 2027 Part D Base Beneficiary Premium Will Be 41 Dollars and 33 Cents, Hitting the Inflation Reduction Act's Annual Cap

CMS set the 2027 Part D base beneficiary premium at 41 dollars and 33 cents in July, representing a 6 percent rise from the prior year and the maximum the IRA allows, a benchmark that shapes what drug plans charge as open enrollment approaches.

By the Goodsurance editorial teamSeptember 19, 2026

The Centers for Medicare and Medicaid Services set the 2027 Medicare Part D base beneficiary premium at 41 dollars and 33 cents, announced July 28. The figure represents a 6 percent increase from the prior year, which is the maximum annual increase the Inflation Reduction Act permits between 2024 and 2029 under its premium stabilization provision.

The base beneficiary premium is a national benchmark CMS calculates each year from Part D plan bids. It does not directly determine what any individual enrollee pays, but it shapes how plan sponsors price their 2027 products and how CMS calculates the benchmark premiums used to determine subsidies for low-income enrollees.

Medicare's 2027 drug plan base premium hits 41 dollars and 33 cents, the maximum allowed under the Inflation Reduction Act, weeks before open enrollment opens.

Reaching the IRA's 6 percent ceiling in 2027 is notable in context. The IRA mechanism was designed to limit year-over-year volatility in Part D costs, but it does not prevent any individual plan's premium from rising by a different amount if the plan's bids diverge from the national benchmark.

The 2027 announcement also came alongside the news that the Part D Premium Stabilization Demonstration, a temporary federal subsidy that cushioned standalone prescription drug plan premiums in 2025 and 2026 beyond the IRA's existing protections, will not continue. The demonstration reduced the base beneficiary premium and capped year-over-year increases for participating plans. Without it, the IRA's 6 percent cap becomes the primary protection against rapid premium growth for standalone Part D enrollees.

Final plan-specific premiums for 2027 are expected to be published by CMS in late September, just ahead of the October 15 open enrollment start.

In plain words

Medicare sets a number each year that helps decide what drug plans charge. For 2027, that number is 41 dollars and 33 cents per month. This is called the base beneficiary premium.

A law called the Inflation Reduction Act says this number can only go up by 6 percent per year. The 2027 number is right at that limit.

This number does not mean everyone pays 41 dollars and 33 cents. Each drug plan sets its own premium. But this number helps set the starting point.

Also, a temporary program that helped keep drug plan premiums lower in 2025 and 2026 is ending. So some people may see bigger changes in what their drug plan charges for 2027.

The full list of 2027 plan prices is expected to be published in late September, just before open enrollment begins on October 15.

Source: CMS
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Federal Watchdog Adds Medicare Part D GLP-1 Overdispensing to Its Active Study List

The Office of Inspector General announced a new evaluation of GLP-1 prescribing patterns in Part D, as the Medicare obesity drug bridge program continues to attract enrollment.

September 17, 2026

Drug prices & Part D

Federal Subsidy That Has Held Down Standalone Medicare Drug Plan Premiums for Two Years Is Ending After 2026

CMS is closing the Part D Premium Stabilization Demonstration after 2026, and a KFF analysis warns that people with standalone prescription drug plans in traditional Medicare could face larger premium increases in 2027 than they have seen in recent years.

September 13, 2026

Drug prices & Part D

Medicare Part D Drug Spending Is Projected to Nearly Double by 2035, With GLP-1 Prescriptions as the Primary Driver

A KFF analysis of the 2026 Medicare Trustees Report projects annual Part D spending will climb from 181 billion dollars in 2025 to 346 billion dollars in 2035, a pace driven largely by surging use of GLP-1 drugs for diabetes and weight loss. The data arrives six weeks before open enrollment opens.

September 11, 2026

Drug prices & Part D

Face-to-Face Drug Price Talks Between Medicare and Manufacturers Close Today on 15 High-Cost Drugs

September 11 is the statutory deadline for in-person and virtual negotiation meetings in Medicare's third drug price negotiation cycle. Written offers are next, with a final CMS offer due September 30 and manufacturer responses due by November 1.

September 11, 2026

Drug prices & Part D

Comment Period Closes September 18 on How Drug Companies Must Apply Medicare-Negotiated Prices at Clinics and Doctor's Offices Starting in 2028

A CMS draft guidance describes the step-by-step process manufacturers must follow to make sure negotiated Medicare prices actually reach patients receiving infused or injected medicines at a doctor's office or outpatient clinic. Public comments are due September 18, 2026.

September 3, 2026

Drug prices & Part D

Medicare's Third Drug Negotiation Cycle Enters Its Final Month Before CMS Must Send Written Offers on 15 Drugs

CMS must issue final written maximum fair price offers to all 15 drug manufacturers in the third negotiation cycle by September 30. Companies then have until October 31 to accept or reject, with any agreed prices published by November 30 and taking effect in January 2028.

September 2, 2026